The combination of dehydroepiandrosterone, transdermal testosterone, and growth hormone as an adjuvant therapy in assisted reproductive technology cycles in patients aged below 40 years with diminished ovarian reserve
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.